Items Tagged ‘advanced’

October 4, 2017

FDA Approves Aliqopa for Relapsed Follicular Lymphoma

By

The U.S. Food and Drug Administration (FDA) granted accelerated approval to Aliqopa® (copanlisib), an intravenously administered pan-class I phosphatidylinositol 3-kinase (PI3K) inhibitor, for the treatment of adults with relapsed follicular lymphoma who have received at least two prior systemic therapies. Follicular lymphoma is the most common indolent (slow-growing) form of non-Hodgkin’s lymphoma (NHL), which is […]

View full entry

Tags: 2016, advanced, ESMO, keytruda, Lung Cancer, News, Non-Hodgkin's Lymphoma, nsclc, opdivo, PD-1, pembrolizumab, Tecentriq